CD51抗体;CD51 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of B16 cells using CD51 mouse mAb (green) and negative control (red).    

  
  

The CD51 antibody targets the CD51 antigen, also known as integrin αV, a subunit of the heterodimeric integrin family receptors. Integrins are transmembrane proteins mediating cell-cell and cell-extracellular matrix (ECM) interactions, crucial for adhesion, migration, signaling, and tissue homeostasis. The αV subunit pairs with various β subunits (e.g., β1. β3. β5. β6. β8) to form distinct integrins (e.g., αVβ3. αVβ5), each recognizing specific ECM ligands like vitronectin, fibronectin, and osteopontin via RGD motifs. CD51 is broadly expressed in endothelial cells, osteoclasts, platelets, and immune cells, and is upregulated in pathological states such as cancer, angiogenesis, and inflammation.

CD51 antibodies are vital tools in research and therapeutics. They block integrin-mediated pathways, offering potential in anti-angiogenic cancer therapies, as αV-containing integrins promote tumor growth and metastasis. In diagnostics, CD51 antibodies help identify αV-expressing cells in tissues, aiding cancer prognosis. They also explore roles in fibrosis, wound healing, and immune regulation. However, challenges remain in specificity due to αV's multiple β pairings, necessitating precise antibody design. Current studies focus on optimizing CD51-targeted agents for conditions like age-related macular degeneration and fibrotic diseases, highlighting its translational significance.